Life support withdrawal for terminally ill: IMA flags concerns, says it will put doctors under stress

The Indian Medical Association has expressed concerns over new guidelines that put the responsibility of deciding on life support withdrawal on doctors. The draft suggests a dual-board system and family consent for terminally ill patients. This aims to help families make informed choices but may stress doctors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qgv3rJ8
via IFTTT

Read More

Venus Remedies get market authorisations for two cancer drugs from Morocco, Philippines

Venus Remedies Ltd has received marketing authorisations for two key oncology drugs, carboplatin and bortezomib, from Morocco and the Philippines. These approvals are part of the company's strategy to expand its oncology range and meet the growing global demand for cancer treatments, strengthening its position in Southeast Asia and Africa.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sqeOPVY
via IFTTT

Read More

Linking spurious drugs with legitimate manufacturers has severe reputational, financial impact: IPA

The Indian Pharmaceutical Alliance (IPA) has called for a clear distinction between spurious and sub-standard drugs following a CDSCO report listing over 50 products as 'not of standard quality'. Major drug firms like Sun Pharma and Glenmark assert that flagged medicines are counterfeits, not their products. IPA emphasizes the need to protect India's reputation as a reliable medicine supplier.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AB0WwEI
via IFTTT

Read More

Regulatory, policy reforms crucial for future of India's pharma R&D: Report

India's regulatory and policy reforms are crucial for the future of pharmaceutical R&D, streamlining approval processes and strengthening IP protections. Despite significant transformation, challenges like inadequate drug regulation capacity and high compliance costs hinder growth. The report suggests promoting India as a hub for pharmaceutical research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sWd74oz
via IFTTT

Read More

Health ministry comes up with new draft guidelines on passive euthanasia

The Union Health Ministry's draft guidelines on passive euthanasia suggest doctors should make considered decisions on withdrawing life support for terminally ill patients based on specific conditions. The guidelines aim to ensure decisions are in the patient's best interests, considering factors like brainstem death and informed refusal by the patient or their kin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKW1Tel
via IFTTT

Read More

Monkeypox in India: Key do's and don'ts you need to follow

The Health Ministry's guidelines for Monkeypox in India stress isolation, testing, and public awareness while urging prompt reporting of cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QJ9s0SU
via IFTTT

Read More

Medical bills in India are rapidly becoming bigger, reveals new index

The ACKO India Health Insurance Index 2024 reveals a 14% annual rise in healthcare costs, with 62% of expenses paid out of pocket. Delhi leads in kidney disease claims, while Kolkata and Mumbai see high heart disease claims. It emphasised the need for improved health coverage to protect individuals from unexpected health crises.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xY9Z6tD
via IFTTT

Read More

EQT to exit AGS Health, eyes $750 million valuation

Swedish fund EQT Partners is set to sell its five-year-old investment in US-based healthcare IT services firm AGS Health, aiming for a valuation of $750 million-$780 million. The sale process, managed by JP Morgan and Bank of America, will launch early next year. AGS Health provides revenue cycle management solutions and employs 12,000 people across multiple locations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F8vrpdQ
via IFTTT

Read More

Want to make India a reliable pharmacy of world, says Secretary Department of Pharmaceuticals

The Indian pharmaceutical industry is emerging as a crucial part of the economy, driven by the success of the Make in India initiative and the Production-Linked Incentive scheme. The sector has seen significant growth in exports and global interest, with many Contract Research, Development, and Manufacturing Organisations establishing operations in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVwZ8TC
via IFTTT

Read More

Sequent Scientific, Viyash Life Sciences announce Rs 8,000 crore merger

Sequent Scientific and Viyash Life Sciences have announced a merger, creating a platform with leadership in animal pharmaceuticals and integrated capabilities across the global pharmaceutical market. The merger will expand Sequent's capital base and is expected to enhance marketing presence, facilitate backward integration, and create procurement synergies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Epe2y4F
via IFTTT

Read More

Carlyle Group portfolio companies in advanced talks for a potential merger

Sequent Scientific, which is in animal health business, posted revenue of around Rs 1,400 crore in FY24. It had earnings before interest, tax, depreciation and amortisation of Rs 100 crore. It has seven manufacturing sites in India, Spain, Brazil and Turkey. Viyash was founded in February 2019 by Hari Babu, formerly the chief operating officer of the world's largest generic drug maker, Mylan, now known as Viatris. Viyash posted FY24 revenue of Rs 1,400 crore with ebitda at Rs 150 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HFoZOyh
via IFTTT

Read More

Suspended eye drops not intended to replace glasses, says Entod CEO

Mumbai-based Entod Pharmaceuticals clarified that its eye drop PresVu is not intended to replace reading glasses for presbyopia. This follows the Indian drug regulator's suspension of its manufacture and sale due to unapproved claims. The company's CEO acknowledged the regulator's decision, stating the eye drop is a therapeutic option.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sl7raSE
via IFTTT

Read More

Paracetamol to pantop: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

The Central Drugs Standard Control Organisation (CDSCO) has flagged over 50 drugs, including Paracetamol, as 'not of standard quality'. The report highlights concerns with various medications such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Some pharmaceutical companies have denied responsibility, claiming the drugs are spurious.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K2c5TqS
via IFTTT

Read More

IHH Health eyes acquisitions to grow business: CEO Prem Kumar Nair

IHH Healthcare plans to double its bed capacity in India to 10,000 beds over the next 4-5 years through brownfield expansion and acquisitions. The group aims to be among the top three healthcare providers in India, expanding into tier-2 cities while maintaining dual brands Fortis and Gleneagles.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uit8jk2
via IFTTT

Read More

Piramal Pharma targets to double revenue in 5 years

Piramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The company plans strategic investments to enhance capabilities in various segments and is also focusing on reducing debt. Currently, CDMO contributes significantly to its revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FScmLoT
via IFTTT

Read More

Health expenditure share against GDP increases from 1.13% in FY15 to 1.84% in FY22

The government health expenditure in India has increased from 1.13% of GDP in 2014-15 to 1.84% in 2021-22, according to the National Health Account estimates. Government spending on healthcare has tripled, while out-of-pocket expenses have significantly decreased, reflecting positive progress towards financial protection and Universal Health Coverage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2de1tLo
via IFTTT

Read More

Testing of drugs from some nations eased

The government has decided to reduce the frequency of testing for drugs imported from certain countries, provided their samples have not failed quality tests in the past five years. Random sampling will be conducted periodically, and any failed samples will lead to increased testing. New sources must undergo compulsory testing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lav8F4d
via IFTTT

Read More

Govt considers random testing of imported medical devices

The government is planning to enhance the quality monitoring of imported medical devices by implementing a risk-based approach. This will involve random sampling for quality tests and full cargo testing for critical diagnostic kits. A guidance document has been issued for port officers to assist in this process, emphasizing the importance of public health safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nEqgRje
via IFTTT

Read More

Common diabetic drug Metformin may become a wonder drug to keep people young; Study finds promising results in monkeys

A recent study has shown that metformin, a diabetes medication, may slow ageing in monkeys by preserving cognitive function and delaying tissue ageing. Conducted by Guanghui Liu's team at the Chinese Academy of Sciences, the research suggests potential benefits for human ageing. Further trials are planned to explore these findings in humans.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fi3xVRW
via IFTTT

Read More

PM Modi to inaugurate Penicillin-G plant in Andhra Pradesh, reviving India's antibiotic production

Prime Minister Narendra Modi is expected to inaugurate a new Penicillin-G plant in Andhra Pradesh, marking the revival of domestic production after three decades. Hyderabad-based Aurobindo Pharma will produce 300 metric tonnes annually, reducing India's dependency on China for this crucial antibiotic component.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F3BlHUY
via IFTTT

Read More

PM Modi pledges USD 7.5 million to Quad Cancer Moonshot to battle cervical cancer

Prime Minister Narendra Modi announced a USD 7.5 million support for cervical cancer sampling kits, detection kits, and vaccines at the Cancer Moonshot event in Delaware. He emphasized India's integrated approach to cancer prevention and treatment, and highlighted India's cost-effective screening program and new AI-driven treatment protocols.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/92JkA7l
via IFTTT

Read More

Quad Cancer Moonshot: PM Modi announces USD 7.5 million support to fight cervical cancer

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MxuDk9G
via IFTTT

Read More

No observations by US FDA during plant inspection: DRL

Dr. Reddy's Laboratories announced that the U.S. Food & Drug Administration (FDA) completed a routine Good Manufacturing Practice (GMP) inspection of its integrated product development organization in Bachupally, Hyderabad, with zero observations. The company shared this update in a stock exchange filing on Friday, highlighting compliance with regulatory standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ilcP7UJ
via IFTTT

Read More

Torrent Pharma gets an observation from USFDA for Pithampur plant

Torrent Pharmaceuticals announced that the USFDA issued a Form 483 with one procedural observation after inspecting its Pithampur manufacturing facility. The inspection took place from September 16-20. Torrent Pharma will respond within the prescribed timeframe and collaborate closely with the USFDA to address the observation. Shares of Torrent Pharma rose by 2.97% on BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wWrzmD0
via IFTTT

Read More

Suven Pharmaceuticals names Vivek Sharma as executive chairman

Suven Pharma, backed by Advent International, has appointed Vivek Sharma as the new executive chairman effective September 20. Sharma brings extensive experience in managing CDMO businesses and will focus on global expansion. The former chairman, Annaswamy Vaidheesh, transitions to vice-chair of Suven’s Advisory council.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wBuPF5J
via IFTTT

Read More

Aster DM Health, Quality CARE inching closer to a merger deal

The merger between Aster DM Healthcare and Quality CARE India is nearing completion, with a deal expected by month-end. The merged entity, Aster DM Quality CARE, will become India's second-largest listed hospital chain. Blackstone and TPG will hold significant stakes but without additional control rights.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Wp8eDx
via IFTTT

Read More

Aurobindo to acquire 49 pc stake in GLS Pharma for Rs 22.5 cr

Aurobindo Pharma Ltd will acquire the remaining 49% stake in GLS Pharma Ltd for Rs 22.5 crore, making it a wholly-owned subsidiary. The acquisition of 5,90,361 equity shares is expected to be completed by December 31, 2024. GLS Pharma specializes in oncology products, including chemotherapy treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sNP7QcY
via IFTTT

Read More

Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Lupin Ltd has signed a non-exclusive patent licence agreement with Takeda Pharmaceutical to commercialise Vonoprazan tablets in India. The drug, approved for various gastrointestinal conditions, will be marketed as Lupivon in 10 mg and 20 mg strengths. This agreement aims to enhance Lupin's gastroenterology portfolio and address unmet patient needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mlbgFur
via IFTTT

Read More

Dispute with Sanofi settled, Panacea scrip soars to over 3-yr high

Panacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High Court case involved Panacea's claim that Sanofi's Shan6 vaccine infringed on its EasySix patent. Sanofi agreed not to market the infringing product and withdrew its opposition to Panacea's patent amendment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/adExQTr
via IFTTT

Read More

Combating counterfeit protein supplements: How genuine brands can lead the fight

The Indian protein supplement market faces challenges with nearly 70% of products containing incorrect information or harmful contaminants. The FSSAI has announced stricter regulations to ensure product safety and accuracy. Industry leaders emphasize the importance of transparency, quality control, and consumer education to combat counterfeit products and maintain trust.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ntfkhqp
via IFTTT

Read More

Panacea, Sanofi settle patent litigation over hexavalent vaccine

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to Panacea's patent. Panacea will forgo claims for damages. The Delhi High Court disposed of the suit on September 13, 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yIdrseM
via IFTTT

Read More

Panacea Biotec, Sanofi settle patent infringement suit

Panacea Biotec has settled a patent infringement dispute with Sanofi Healthcare India regarding its fully liquid hexavalent vaccine, EasySix. Sanofi agreed not to launch its Shan6 vaccine in India and will withdraw oppositions against Panacea's patent amendment application. The Delhi High Court disposed of the suit on September 13, 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8htzvEp
via IFTTT

Read More

Polymed lines up ₹750 crore for expansion, buys over two years

The company last month raised ₹1,000 crore through qualified institutional placement (QIP) and has ₹150 crore as free cash flow to fund its growth plans. Polymed makes disposable medical items, such as IV cannula, blood bags, blood collection tubes, and infusion and transfusion sets. About two-thirds of sales come from infusion therapy products. The company spends 2% of revenue on R&D.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6mYKvcz
via IFTTT

Read More

Laurus Labs opens new R&D facility in IKP Knowledge Park, Hyderabad

Laurus Labs has inaugurated a new R&D facility at IKP Knowledge Park near Hyderabad, investing Rs 250 crore. The 200,000 square foot center will support their CDMO business and create over 800 jobs. The facility aims to develop innovative solutions for unmet medical needs, according to CEO Satyanarayana Chava.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MkSy8au
via IFTTT

Read More

30-30-30 method for weight loss: What is it and does it really work?

The 30-30-30 method involves a high-protein breakfast, followed by 30 minutes of exercise. It boosts metabolism, aids weight loss, and is easy to maintain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jTOntgC
via IFTTT

Read More

How intravenous drips of vitamins are becoming popular and why doctors flag them as unnecessary

A person associated with a wellness centre in Gurgaon says on condition of anonymity that the vitamin IV “therapy” is gaining traction and the footfall the centre is getting is increasing every month. “The number of people opting for IV vitamins has gone up by 30-40% over last year,” he says, adding, “We offer packages depending on what one wants. A screening is done by our in-house doctor and then a cocktail is decided.” Instead of popping multivitamin tablets, why do people opt for intravenous drips? “When vitamins are taken orally, the absorption rate is 20-50%. However, it is 90-100% when it is given intravenously,” the person says. It is sought by people in the metros, he adds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MbpW7Gf
via IFTTT

Read More

Drug sales get a monsoon twist in August

Liver herbal supplement Liv 52 emerged as one of India's top-selling herbal tonics in August, driven by increased cases of liver-related illnesses during the monsoon season. The Indian pharmaceutical market saw a 6.3% growth year-over-year, with gastrointestinal and anti-diabetic medications performing strongly in both sales value and volume.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EyuMvXq
via IFTTT

Read More

Ayushman Bharat enrollment for senior citizens to start in a week

Enrollment for senior citizens aged 70 and above under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) will begin soon. Initially launching as a pilot program, eligible seniors can apply through the Ayushman mobile app or PMJAY portal. The scheme offers free health insurance coverage of up to Rs 5 lakh annually on a family basis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yDRJhuM
via IFTTT

Read More

Healthcare, manufacturing sector to benefit most from Fed rate cuts: Motilal Oswal

As the U.S. Federal Reserve's anticipated rate cut approaches, a report by Motilal Oswal suggests that the healthcare and manufacturing sectors are expected to benefit the most. Healthcare is projected to be the fastest-growing sector, while manufacturing may see technological advancements. Challenges remain for BFS, retail, and hi-tech industries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rd8yeFZ
via IFTTT

Read More

Alkem joins $3 bn race for JB Chem as Torrent pauses talks

Alkem Laboratories, India's fifth-largest branded pharmaceutical company, is vying for JB Chemicals and Pharmaceuticals as KKR looks to sell. Torrent Pharmaceuticals has exited negotiations over valuation differences. If successful, this will be Alkem's largest acquisition, enhancing its presence in the chronic segment and potentially moving it to fourth place in the domestic formulations market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WFzC6X1
via IFTTT

Read More

Kiran Mazumdar-Shaw calls for innovation-driven value creation in India's biotech sector

Biocon Chairperson Kiran Mazumdar-Shaw urges increased investment in research and development to drive innovation and intellectual property culture. Speaking at Global Bio-India 2024, she highlights India's potential as a global bio-innovation hub, emphasizing its scientific talent and technological capabilities. She also underscores the importance of biotechnology in healthcare and agriculture.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sRV9xg0
via IFTTT

Read More

DNA Wellness to invest Rs 200 cr to set up over 100 cervical cancer screening labs

Ahmedabad-based DNA Wellness will invest Rs 200 crore to establish over 100 cervical cancer screening labs across India by 2027. The company has exclusive rights to conduct the DNA Ploidy Test, developed by the British Columbia Cancer Research Agency. The first CERViSure lab has been launched in Ahmedabad, with plans for more labs in Gujarat by October 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mSZtNxk
via IFTTT

Read More

Durex makes India condom push for women, rural consumers

Reckitt Benckiser, the world's largest condom maker, is shifting its focus in India to target women and rural consumers. With changing attitudes towards female pleasure and a rise in condom use among Indian women, Reckitt is reformulating products and launching new marketing campaigns. The company faces challenges with distribution, pricing, and conservative societal norms but sees significant growth potential in India's expanding market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2gnU5Zl
via IFTTT

Read More

DCGI suspends nod to Entod's new eye drops over unapproved 'claims'

India's drug regulator has suspended Entod Pharmaceuticals' permission to manufacture and sell PresVu Eye Drops. The company did not obtain clearance for its claim that the drops reduce dependency on reading glasses for presbyopia. Entod plans to challenge the suspension in court, asserting that their clinical trials demonstrated efficacy and safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dh4IsHS
via IFTTT

Read More

Bharat Biotech inks pact with Alopexx for anti-microbial vaccine

Bharat Biotech has partnered with Alopexx, Inc. to co-develop and commercialize the anti-microbial vaccine AV0328 in India and other low-income countries. The collaboration aims to address antimicrobial resistance through vaccination, with Alopexx receiving upfront and milestone payments, as well as royalties on future sales in licensed territories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tMWp0zS
via IFTTT

Read More

Jaggery or sugar: Which sweetener is better for your health?

Jaggery is healthier due to its nutrient content, lower glycemic index, liver detox benefits, digestive aid, immune boost, and minimal processing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3QicrD
via IFTTT

Read More

8 essential plants you should have for a mosquito-free home

Looking for natural ways to keep mosquitoes at bay? Incorporating mosquito-repelling plants into your garden or home can be both effective and aesthetically pleasing. Here are eight plants that not only enhance your outdoor space but also help keep pesky insects away.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/N7XljdL
via IFTTT

Read More

US animal health major Zoetis expands GCC in Hyderabad, to add 300 jobs by 2025

Zoetis, the world's largest producer of pet and livestock medicine, is expanding its global capability centre in Hyderabad. The centre will add around 300 technology jobs by next year and support the company's global operations using advanced technology tools. This expansion aims to leverage Hyderabad's tech talent pool and life-science ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qSGvzW4
via IFTTT

Read More

Plant for production of Penicillin G & Clavulanic acid to start soon: Department of Pharmaceuticals

The Department of Pharmaceuticals has announced that India will soon start producing Clavulanic Acid, a key ingredient in the antibiotic Augmentin. This move is part of the Production Linked Incentive scheme aimed at reducing dependency on foreign imports and boosting local manufacturing of essential bulk drugs like Penicillin G and Clavulanic Acid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zKT5GCB
via IFTTT

Read More

Johnson & Johnson told to pay ₹35 lakh each as compensation to hip implant victims

The National Consumer Disputes Redressal Commission has ordered Johnson & Johnson to pay ₹35 lakh in compensation to each patient affected by a faulty hip implant. The commission also mandated an interest of 6% per annum on the compensation from the complaint filing date. The payment must be made within two months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TkCvjgN
via IFTTT

Read More

Fortis seeks CCI nod to buy 31.52% more in diagnostics subsidiary Agilus

Fortis Healthcare has sought approval from the Competition Commission of India to acquire an additional 31.52% stake in its diagnostics arm, Agilus, raising its shareholding to 89.2%. The deal, valued at ₹1,780 crore, involves buying stakes from private equity players. Additionally, Aquilo House Pte seeks approval to acquire a 26.47% stake in Aavas Financiers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d1TNWH4
via IFTTT

Read More

EQT to acquire ChrysCap-owned healthcare BPO GeBBS

Swedish Private Equity fund EQT has acquired GeBBS Healthcare Solutions from ChrysCapital for approximately $860-870 million. GeBBS, a provider of revenue cycle management services, has seen significant growth under ChrysCapital's ownership. The acquisition aligns with EQT's focus on healthcare technology and aims to further accelerate GeBBS' growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3FzQaBW
via IFTTT

Read More

Looking to lose weight? Try these 6 bedtime yoga poses!

These poses, done consistently, can aid in weight loss by reducing stress, improving digestion, and promoting better sleep.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d9Ytn05
via IFTTT

Read More

Building muscle mass: Why the growing lure of protein supplements is worrying health experts

The protein revolution is transforming diets across India, with many turning to supplements to meet their nutritional needs. This trend is driving a booming industry but also raising concerns about the indiscriminate use of protein powders. Experts advocate for balanced diets and caution against over-reliance on marketed products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VioM3mr
via IFTTT

Read More

7 bad habits to avoid after 40 for a healthier life

Here are seven bad habits to quit after 40 to improve health and well-being:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRDKClo
via IFTTT

Read More

Wockhardt says acted as per laws, denies Congress' charges over affiliate rental payments to Sebi chief

Wockhardt has refuted allegations of conflict of interest and corruption made by the Congress party against SEBI chairperson Madhabi Puri Buch. The claims relate to rental payments by Carol Info Service, an affiliate of Wockhardt, which is involved in multiple cases with SEBI, including insider trading. Wockhardt termed the allegations as baseless and misleading.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rUGg3dR
via IFTTT

Read More

India takes tiny steps back from its China dependency

India is striving to reduce its dependency on China for pharmaceutical raw materials by promoting domestic production through a Production-Linked Incentive scheme. Companies like Kinvan and Aurobindo Pharma are stepping up to produce essential components locally, aiming for self-sufficiency in the pharma sector, especially highlighted during the Covid pandemic.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n1yklau
via IFTTT

Read More

Novo Nordisk not yet ready to bring in popular obesity, diabetes injectables

Novo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The company is scaling up production and may consider local fill-finish options. Currently, the injectable forms are not approved in India, leading to high demand in grey markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xHSkP0l
via IFTTT

Read More

Strides gets USFDA nod for Theophylline extended-release tablets

Strides Pharma Science Ltd announced that its subsidiary has received approval from the USFDA for its generic version of Theophylline extended-release tablets, used to manage chronic asthma and other respiratory conditions. The tablets, available in 300 mg and 450 mg doses, will be produced at their Bengaluru facility and have a market size of around USD 11.5 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dDlAq1O
via IFTTT

Read More

India starts making key API clavulanic acid

India has begun producing clavulanic acid, a key ingredient in the antibiotic Augmentin, reducing its reliance on China for APIs. Mumbai-based Kinvan is leading this initiative, with plans to scale up production to 300 metric tons by the end of the year. This move aligns with India's production-linked incentive scheme.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x8qYw7W
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic product

Alembic Pharmaceuticals has received approval from the USFDA to market Albendazole Tablets USP (200 mg), a generic drug for treating infections caused by worms. The tablets are equivalent to Impax Laboratories' Albenza and are used for conditions like parenchymal neurocysticercosis and cystic hydatid disease. Alembic Pharma shares rose 2.79% on Thursday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tl8GQaC
via IFTTT

Read More

Need to strike fine balance between making hospitals secure and accessible: AIIMS-Delhi director

Dr. M Srinivas, Director of AIIMS-Delhi, has highlighted the need for balancing hospital security and accessibility amid demands for a safer work environment following the RG Kar rape-murder case. He underlined the importance of improving infrastructure and working conditions for medical professionals while ensuring patient care remains a priority.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SGpDgnU
via IFTTT

Read More

Potential outbreak-causing dangerous viruses found in China’s fur animals

Scientists have discovered novel and potentially dangerous viruses in raccoon dogs, mink, and other fur-farmed animals in China. The study found 125 virus species, including 36 novel ones, with 39 posing a high risk of crossing the species barrier. This highlights the need for better virus surveillance in fur-animal farming.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aUwg9mO
via IFTTT

Read More

EQT set to acquire BPO GeBBS from ChrysCapital

Swedish private equity fund EQT is set to acquire Los Angeles-based healthcare BPO company GeBBS Healthcare Solutions for about $870 million. The deal, which outbid Hillhouse Investment, is expected to be signed soon. GeBBS, founded in 2005, employs 14,000 workers globally and competes with major firms like Wipro and IBM.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ncdX7e0
via IFTTT

Read More

Lactose intolerant? 6 top non-dairy calcium sources for healthy bones

Here are 6 non-dairy sources of calcium that are great for maintaining healthy bones:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BAuIFPY
via IFTTT

Read More

Natco Pharma acquires 40 million shares in eGenesis Inc

Natco Pharma's Canadian subsidiary has acquired 40 million shares in eGenesis Inc. for USD 8 million. eGenesis is a biotechnology company developing human-compatible organs for transplant through xenotransplantation. This investment aims to support eGenesis' pioneering work in kidney, liver, and heart transplants, potentially addressing the global transplant shortage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0X8Lkc5
via IFTTT

Read More

No link between mobile phones and brain cancer, WHO-backed study says

A World Health Organization-commissioned review has found no link between mobile phone use and an increased risk of brain cancer. The study, which analyzed data from 63 studies between 1994 and 2022, showed no rise in brain cancer cases despite the surge in wireless technology usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ry2vViu
via IFTTT

Read More

Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the board

Cipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamied will join as a non-executive director from November 1, 2024. Cipla also appointed Adil Zainulbhai and Abhijit Joshi as additional directors starting September 3, 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/h0PqOS9
via IFTTT

Read More

Cipla's MK Hamied resigns from the company due to health reasons

Cipla's Vice Chairman and Non-Executive Director, Mr. M K Hamied, has resigned from his position due to age and health reasons. His resignation will be effective from the close of business hours on October 29, 2024. In a letter to employees, Hamied expressed pride in his tenure and confidence in Cipla's future success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBGapOy
via IFTTT

Read More

Mankind: How Meerut brothers built India's 4th largest pharma firm

Mankind Pharma has announced a significant move by acquiring Bharat Serums and Vaccines Ltd for Rs 13,630 crore. The acquisition, partly funded by debt, aims to strengthen Mankind’s portfolio. The Juneja brothers are confident in their strategy despite market concerns about integration and cost.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nbZ3jD2
via IFTTT

Read More

Mankind Pharma eyes ₹9,000 cr via debt to stitch BSV deal

The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. "Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand," said one of the persons.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kcw4QbH
via IFTTT

Read More

Alkem inks licensing pact with Takeda to introduce Vonoprazan in India

Alkem Laboratories has entered into a patent licensing agreement with Takeda Pharmaceutical to market Vonoprazan in India. This medication is used to treat conditions like reflux esophagitis and various ulcers. This licensing deal will enhance Alkem's offerings in the gastrointestinal segment, according to CEO Vikas Gupta. The company's shares dropped 1.66% on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ulcrmtk
via IFTTT

Read More

How to control blood sugar naturally: 7 tips

Discover seven natural strategies to balance blood sugar levels, including increasing fiber intake, staying hydrated, exercising, and managing stress effectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f0gCyh7
via IFTTT

Read More

Biocon unit gets USFDA nod for generic drug

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u6aRht3
via IFTTT

Read More

AI-powered device successfully treats blood clot in a 28-year-old

A 28-year-old man with acute pulmonary thromboembolism was successfully treated at Sir Gangaram Hospital using an AI-powered device designed to remove blood clots accurately. The device prevents severe blood loss by targeting only clots. This method avoids the risks associated with conventional treatments like internal bleeding and repeated interventions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/weUABvg
via IFTTT

Read More